And platinum pharmaceutical in the Hong Kong Stock Exchange submitted an IPO application more than 10 in the research of new drugs to help the capital road.

On August 18, and Platinum Pharma filed for an IPO on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities and CITIC Securities as co-sponsors.
, and Platinum Pharma applied for listing on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules.
fund raising will be used in part for the clinical development of three pillar products: FcRn inhibitors, TNF-α inhibitors and anti-CTLA-4 antibodies.
Screenshot Source: And Platinum Pharmaceuticals prospectine Following the completion of the $85 million B round of financing in August 2018, the company completed a $75 million B-plus round of financing in March this year and a $102.8 million round of C financing in July this year.
C round of financing is led by Hudson Bay Capital, with the participation of Obo Capital, Guiyuan Ventures, Gautejia Investment Group, Ruizhi Capital, etc.
's proprietary antibody platform, based on the prospectines, and Platinum Pharma is equipped with a full suite of highly efficient antibody discovery and technologies that enhance or amplification antibody efficacy, including the HCAb platform as an extension of important technologies and the HBICETM platform.
, the HCAb platform can be used to develop new (heavy chain only) antibodies, while the HBICETM platform can be used to develop highly differentiated HCAb-based immune cell bridger dual-specific antibodies.
currently, and platinum medicine has established a wealth of pipelines in research, of which six projects have entered the clinical stage.
and Platinum Pharmaceuticals are in the process of developing products (Photo Source: Reference 1) 1, FcRn inhibitor Bartoli monoanti (HBM9161) Bartoli monoanti is a new all-human monoclonal antibody for binding and inhibiting specific neonatal Fc subjects (FcRn).
FcRn plays a key role in preventing the degradation of IgG antibodies, high levels of pathogenic IgG antibodies can induce a variety of autoimmune diseases.
in preclinical and clinical trials, Bartoli monoantigen has demonstrated its best-in-class potential, not only significantly reducing IgG antibody levels, but also performing well in terms of safety.
addition, Bartoli monoantigen is being developed as a drug treatment for suture injections, which are simpler, more convenient and can be injected at home. according to the
prospectine, and Platinum Pharma have launched a phase 1b/2 trial of optic neurospinal cord disease in January this year, and a phase 2/3 registration trial for immunoplate platelet reduction in March this year, as well as a phase 2 clinical trial of severe muscle weakness.
, Platinum Pharmaceuticals plans to begin a phase 3 registration trial for thyroid-related eye disease in 2021.
Taking into account China's recently revised policy on rare diseases, Platinum Pharmaceuticals plans to apply for breakthrough therapeutic drugs for optic neurospinal cord disease and severe muscle weakness in the first half of 2021 in order to seek special channels such as rapid review and priority review.
2, TNF-α inhibitor Ternasip (HBM9036) Ternasip is the fastest-growing candidate for platinum medicine in the research pipeline, the mechanism of action is to inhibit the TNF-α, which causes inflammation of the eye.
studies have shown that Ternasip can significantly improve a patient's signs, be safe and be quick.
phase 3 test conducted in the United States and phase 2 trial in China, the total score (TCSS) of the upper cornea, central cornea and lower cornea fluorescence staining examination was significantly improved.
, the product is currently in China to carry out phase 3 registration trials.
note that both products were developed by HanAll Biopharma and Platinum Pharmaceuticals introduced their development and commercial interests in Greater China.
3, anti-CTLA-4 antibody HBM4003 HBM4003 is one of the pillar assets in the pipeline of platinum pharmaceutical tumor immunological products, for a new generation of all-human source anti-CTLA-4 antibody.
According to the prospecto, HBM4003 is an all-human source heavy chain antibody that entered the clinical development phase earlier, and is the company's first in-house developed molecule that has advanced from the drug candidate screening phase to the clinical phase in about 3 years.
prospectus shows that based on preclinical data, HBM4003 exhibits unique and good characteristics, including: 1) the ability to consume in-tumor regulatory T cells by enhancing ADCC as a strategy, thus having great potential to break the significant immunosuppressive barrier of solid tumor immunotherapy;
currently, and Platinum Pharmaceuticals has developed HBM4003 as a monotherapy and is conducting Phase 1 clinical trials in Australia for patients with advanced solid tumors, with key data expected by early 2021.
in the United States, the product was approved by IND in January this year.
addition, the company has begun to develop HBM4003 as a combination therapy, used in combination with PD-1 to treat advanced solid tumors (including melanoma, MSI-H colorectal cancer and non-small cell lung cancer), and has been approved in clinical trials in China.
4, HER2/CD3 dual-specific antibody HBM9302 HBM9302 is a dual-specific antibody for HER2 and CD3, which binds to the overexposed HER2 molecule and CD3 molecule expressed on the surface of T cells in solid tumor patients, connects cytototoxic T cells to HER2-positive cancer cells, and plays its cytotoxic effect on tumor cells.
in preclinical studies, the product has shown good anti-tumor activity.
HBM9302 was developed by Ichnos and Platinum Pharmaceuticals was granted an exclusive license in 2018 to develop the product in Greater China.
, HBM9302 is currently being tested in Phase 1 dose incremental clinical trials by Ichnos in Germany and the United States, using a single drug to treat HER2-positive cancer subjects.
, Ichnos has launched another Phase 1 clinical trial for HER2-positive metastasis breast cancer subjects who progressed after treatment.
Pharmaceuticals plans to file an IND application for HBM9302 for herl2-positive breast and stomach cancer in China in the first half of 2021.
In addition, and platinum medicine has a number of early stages of development in the research project, including: 1) HBM7020, a new type of dual-specific antibody for BCMA and CD3, containing HCAb immune cell bridger; 7015, a new type of dual-functional fusion protein containing PD-L1-inhibited all-human source IgG1 monoclonal antibodies and soluble extracellular regions of the transformation growth factor β orceptor II (TGFbR2);
: 1 and Platinum Pharmaceuticals HKEx IPO prospectos. Retrieved Aug 18, 2020, from s2 and platinum pharmaceutical official website and public information.